Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597854 | 0.79 | TP53 (0.41) | NPC1RAB9AKMT2AMEN1MTNR1A | |
| SCHEMBL21603867 | 0.77 | TP53 (0.39) | EPHX2NPC1RAB9AMTNR1AMTNR1B | |
| SCHEMBL28624417 | 0.77 | KMT2A (0.40) | RAB9AKMT2AMEN1MTNR1AMTNR1B | |
| SCHEMBL21603645 | 0.76 | EPHX2 (0.46) | EPHX2NPC1RAB9AEPHX1MTNR1A | |
| SCHEMBL21597559 | 0.76 | EPHX2 (0.45) | EPHX2NPC1RAB9AEPHX1KMT2A | |
| SCHEMBL28609236 | 0.75 | TP53 (0.36) | NPC1RAB9AMTNR1AMTNR1B | |
| SCHEMBL28622749 | 0.75 | TP53 (0.36) | NPC1RAB9AMTNR1AMTNR1B | |
| SCHEMBL21603763 | 0.73 | TP53 (0.39) | NPC1RAB9AKMT2AMEN1HPGD | |
| SCHEMBL21603764 | 0.72 | ALDH1A1 (0.54) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL21597427 | 0.72 | TBXAS1 (0.46) | NPC1RAB9AKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | EPHX2 1603/4885NPC1 185/4885RAB9A 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.